Biomedicine / Biomedicine and medical devices / Complete systems and use-case applications Supply-chain Study

Comparative structure study

The largest recorded reporting jurisdiction, Jiangsu, contains 185 records (14.3% of this 1,292-record cohort). The remaining cohort contains 1,107 records. The comparison concerns archive composition.

The recorded sub-industry label Biomedicine accounts for 47.5% here (614/1,292), compared with 46.8% in the parent set (643/1,373), an absolute gap of 0.7 percentage points.

482/1,292 companies link to pages with existing source-supported excerpts (37.3% of the cohort). The other 810 records remain usable for archive composition, but do not support new operating case studies.

An ID-deduplicated archive snapshot, not the whole market, current recognition or operating results.

The parent set, Biomedicine and medical devices / Complete systems and use-case applications, contains 1,373 records. This cohort contributes 1,292 (94.1%); 81 records remain after excluding it.

The parent set, Biomedicine, contains 1,721 records. This cohort contributes 1,292 (75.1%); 429 records remain after excluding it.

Ratio of label participation, not market share; multi-label counts overlap.

Excluding this cohort, the recorded sub-industry label Biomedicine covers 29/81 remaining records (35.8%), an absolute gap of 11.7 percentage points from this cohort.

The full reporting jurisdiction distribution has 36 labels; the top 3 contain 460/1,292 records (35.6%).Other known labels contain 832 records.

For 1,292 records with known labels, the effective category count is 14.4, versus 36 actual labels. Definitions and scope are in the methodology.

The table shows ten labels; 26 others are included in the calculations above.

Record counts do not rank supply capability or economic size.

Non-empty fields are not necessarily accurate or supported by originals.

Counts concern existing reviewed bilingual excerpts, not re-certification of originals or entire reports.

A rule hit prioritises review; it does not establish that the entire field is wrong. One record can trigger several rules.

258 of this cohort’s 1,292 records link through existing company-ID mappings to 2026 lists from all jurisdictions (20.0%). This intersection measures list linkage, not successful recognition or company growth.

List rows and company IDs are separate counts, not new firms or final recognition.

Drug-production leads need validation and change records

The Chemical drugs and formulations label covers 143 records (11.1% of this cohort). This archive clue raises a verification question about Defined pharmaceutical-production or testing services with quality documents; it does not establish that these companies already deliver it.

Shared records with Biomedicine and medical devices / Complete systems and use-case applications Supply-chain Study: 1,292; records in this cohort but outside that set: 0. The intersection/union ratio is 94.1%, a measure of label overlap rather than business collaboration. Read comparison

Shared records with Biomedicine / Biomedicine and medical devices / Complete systems and use-case applications Sub-industry and Supply-chain Study: 614; records in this cohort but outside that set: 678. The intersection/union ratio is 46.5%, a measure of label overlap rather than business collaboration. Read comparison

Stable-ID samples, not rankings; metrics use the full cohort.